74
Participants
Start Date
February 24, 2020
Primary Completion Date
January 8, 2025
Study Completion Date
January 8, 2025
GTX-102
antisense oligonucleotide
The Royal Children's Hospital, Parkville
Austin Health, Heidelberg
Weill Cornell Medicine, New York
Universitatsklinikum Hamburg-Eppendorf, Hamburg
Rare Disease Research, Atlanta
Rush University Medical Center, Chicago
AP-HP Hopital Necker-Enfants Malades, Paris
UCLA Medical Center, Los Angeles
Rady Children's Hospital, San Diego
Boston Children's Hospital, Boston
Queensland Children's Hospital, South Brisbane
MAGIC Clinic Ltd, Calgary
British Columbia Children's Hospital, Vancouver
Children's Hospital of Western Ontario, London
McGill University Health Centre, Montreal
Hopital de la Timone, Marseille
The Edmond and Lily Safra Children's Hospital, Ramat Gan
Hospital Sant Joan de Deu, Esplugues de Llobregat
Hospital Universitari Parc Tauli, Sabadell
Hospital Universitario Puerta de Hierro, Majadahonda
Cambridge University Hospitals, Cambridge
Great Ormond Street Hospital for Children, London
Children's Hospital of Eastern Ontario, Ottawa
Universitatsklinikum Leipzig, Leipzig
Oxford University Hospitals NHS Foundation Trust, Oxford
Ultragenyx Pharmaceutical Inc
INDUSTRY